The Joint (JYNT) Q3 2025: Adjusted EBITDA Up 36% as Franchise Model Pivot Accelerates
The Joint’s accelerated shift to a pure-play franchise model and cost discipline drove a 36% adjusted EBITDA gain, even as system-wide sales slipped. Leadership is betting on national marketing, digital tools, and dynamic pricing pilots to reverse negative comps and support long-term franchisee economics. The refranchising strategy, national brand push, and robust cash position set up a structurally leaner business for 2026, but near-term growth depends on patient acquisition and successful pricing execution.
Summary
- Franchise Model Transition: Refranchising of company clinics is reshaping the cost base and revenue mix.
- Marketing Overhaul: National pain-relief messaging and digital upgrades aim to reignite patient growth.
- 2026 Profit Leverage: Cost reductions and a pure franchise model are expected to lift margins next year.
Performance Analysis
The Joint delivered 6% revenue growth from continuing operations in Q3, driven mainly by a higher number of franchise clinics, even as system-wide sales declined 1.5% and same-store sales (comps) fell 2%. The company’s cost structure improvements—including a 6% drop in cost of revenues and a 3% reduction in G&A—enabled a 36% increase in consolidated adjusted EBITDA, marking a clear divergence between top-line sluggishness and operational efficiency gains.
Clinic openings and franchise license sales remained steady, with nine new franchise clinics opened and eight licenses sold in the quarter. Early results from new pre-opening protocols are accelerating break-even timelines for new clinics to under a year, compared to around two years previously. Cash reserves rose to $29.7 million, supporting both operational flexibility and a stepped-up buyback program, as 540,000 shares were repurchased since August and the board authorized another $12 million for repurchases.
- Cost Structure Realignment: G&A and cost of revenues declined despite revenue growth, reflecting refranchising progress.
- Clinic Performance Spread: New clinics are reaching break-even faster due to enforced pre-opening lead generation protocols.
- Marketing Spend Shift: Franchisees reallocated $500/month per clinic from local to national campaigns, amplifying brand reach.
Despite improved profitability, negative comps and lower new patient counts remain a concern, putting pressure on upcoming marketing and pricing initiatives to deliver volume recovery.
Executive Commentary
"Although the full financial benefit of these strategies will take time to come to fruition, the following initiatives will improve the financial position of our franchisees and stockholders."
Sanjeev Razdan, President and Chief Executive Officer
"Reflecting our re-franchising efforts and realignment of our corporate cost structure, we have made significant progress reducing our operating costs. As a result, we expect 2026 continuing operations to be more profitable than 2025."
Scott Bowman, Chief Financial Officer
Strategic Positioning
1. Franchise Model Acceleration
The Joint is rapidly executing a transition to a pure-play franchisor model, aiming to divest all remaining company-owned clinics. An initial agreement to sell 45 Southern California clinics for $4.5 million is in process, with 33 more clinics targeted for refranchising. This shift is designed to reduce corporate overhead, increase royalty revenue mix, and improve margin stability by eliminating direct clinic operating costs.
2. National Marketing and Brand Refresh
Leadership is pivoting from local to national marketing spend, with franchisees now contributing a portion of gross sales to a centralized campaign. The new “Life Unpaused” initiative focuses on pain relief, reflecting research that 80% of new patients seek chiropractic care for aches and pains. SEO improvements and clinic microsites are already driving 20% to 40% organic search traffic gains in pilot locations, broadening the top-of-funnel and aiming to reverse declining new patient counts.
3. Dynamic Pricing and Revenue Management
Three-tiered pricing pilots for the core wellness plan launched in November, testing patient sensitivity to price increases across 200 clinics. The goal is to identify the optimal balance between accessibility and margin recovery, with a system-wide rollout targeted for Q1 2026. The “Kick Start” plan, a new package of additional adjustments for acute pain, has already seen 25% uptake among new patients, driving incremental revenue per clinic.
4. Patient Experience and Digital Engagement
Patient-facing technology upgrades, including a revamped mobile app, are central to improving retention and lifetime value. With 178,000 downloads and 18% of new patients adopting the app, early feedback is positive. Upcoming features—such as gamification and self-service tools—are expected to further reduce friction and extend plan tenure.
5. Operational Discipline and Cost Reduction
Right-sizing G&A, renegotiating regional developer royalties, and focusing on scalable franchise support are key levers for margin expansion in 2026 and beyond. The company is targeting further reductions in salaries, benefits, insurance, and ancillary costs as the refranchising process completes.
Key Considerations
The Joint’s Q3 underscores a structural pivot and operational reset, but volume growth remains elusive as comps stay negative. Execution on marketing, pricing, and franchisee economics will determine the sustainability of margin gains.
Key Considerations:
- Franchise Model Execution: Timely completion of refranchising is critical to unlocking full cost leverage and recurring royalty streams.
- Marketing ROI Uncertainty: National campaigns and SEO upgrades must drive measurable new patient growth to offset recent declines.
- Pricing Power Test: The ability to raise prices without accelerating attrition will be a key indicator of brand strength and patient loyalty.
- Clinic Performance Variability: New protocols are shortening break-even for openings, but mature clinic comps remain under pressure.
- Cash Deployment Discipline: Strong cash reserves and buybacks provide flexibility, but capital allocation must be balanced with long-term growth investments.
Risks
The primary risk lies in patient acquisition lagging expectations, as negative comps and lower new patient counts could undermine franchisee economics and system-wide growth. Macroeconomic headwinds and lender constraints may slow refranchising progress. Unsuccessful pricing increases risk further attrition if patient price sensitivity is underestimated. Execution on national marketing and digital engagement must deliver tangible volume recovery to sustain the franchise model’s economics.
Forward Outlook
For Q4 2025, The Joint guided to:
- System-wide sales of $530 to $534 million (narrowed from $530-$550 million)
- Comp sales in the range of negative 1% to flat (lowered from prior low-single-digit increase)
For full-year 2025, management maintained:
- Consolidated adjusted EBITDA of $10.8 to $11.8 million
- New clinic openings of 30 to 35
Management highlighted several factors that will shape 2026:
- Expectations for higher profitability from continuing operations post-refranchising
- System-wide pricing adjustments planned for Q1 2026, pending pilot results
Takeaways
The Joint’s franchise pivot and cost controls are delivering margin gains, but growth now hinges on reversing negative comps through marketing and pricing execution.
- Profitability Leveraged by Franchise Model: Operating cost reductions and royalty-driven revenue streams are structurally lifting margins, with further gains expected as refranchising completes.
- Patient Acquisition is the Critical Watchpoint: National brand campaigns and digital upgrades must deliver new patient growth to sustain system-wide sales and franchisee health.
- Pricing Power and Retention Under Test: Q1 2026 will be pivotal as pricing pilots determine whether the brand can capture higher revenue per patient without driving attrition.
Conclusion
The Joint is at a strategic crossroads: Leaner operations and a full-franchise model promise improved profitability, but the next phase depends on reigniting patient demand and demonstrating pricing power. Investors should watch new patient trends, comp sales, and the pace of refranchising as the clearest signals of sustainable growth.
Industry Read-Through
The Joint’s experience highlights a broader challenge for retail health and wellness franchises: balancing cost leverage from franchising with the need for ongoing patient acquisition in a competitive, price-sensitive market. National brand building and digital-first patient engagement are emerging as key differentiators, while macro headwinds and lender caution may slow refranchising across the sector. Other health service franchises should note the importance of dynamic pricing, robust pre-opening protocols, and scalable digital tools to drive both unit-level economics and system-wide growth in a maturing market.